S&P 500

6.032,38

0,56%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
AMEX
Can Fite BioPharma Ltd (CANF)
Can Fite BioPharma Ltd (CANF) Notícias

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:AMEX:CANF

1 2 3 4 5 6 7 8 9 10 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
14/11/2024	18:48	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	AMEX:CANF	Can Fite BioPharma Ltd
11/11/2024	09:00	GlobeNewswire Inc.	Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial	AMEX:CANF	Can Fite BioPharma Ltd
04/11/2024	09:09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
04/11/2024	09:08	GlobeNewswire Inc.	Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia	AMEX:CANF	Can Fite BioPharma Ltd
18/10/2024	10:06	GlobeNewswire Inc.	Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson	AMEX:CANF	Can Fite BioPharma Ltd
09/10/2024	08:00	GlobeNewswire Inc.	FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer	AMEX:CANF	Can Fite BioPharma Ltd
07/10/2024	08:00	GlobeNewswire Inc.	Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29	AMEX:CANF	Can Fite BioPharma Ltd
24/09/2024	08:00	GlobeNewswire Inc.	Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis	AMEX:CANF	Can Fite BioPharma Ltd
16/09/2024	08:00	GlobeNewswire Inc.	Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health	AMEX:CANF	Can Fite BioPharma Ltd
09/09/2024	01:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:CANF	Can Fite BioPharma Ltd
06/09/2024	17:30	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	AMEX:CANF	Can Fite BioPharma Ltd
30/08/2024	17:18	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	AMEX:CANF	Can Fite BioPharma Ltd
30/08/2024	17:16	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	AMEX:CANF	Can Fite BioPharma Ltd
30/08/2024	17:15	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	AMEX:CANF	Can Fite BioPharma Ltd
29/08/2024	09:15	GlobeNewswire Inc.	Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies	AMEX:CANF	Can Fite BioPharma Ltd
08/08/2024	20:01	GlobeNewswire Inc.	Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds	AMEX:CANF	Can Fite BioPharma Ltd
29/07/2024	08:00	GlobeNewswire Inc.	Can-Fite Provides Namodenoson Patent Update	AMEX:CANF	Can Fite BioPharma Ltd
17/07/2024	08:00	GlobeNewswire Inc.	Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8	AMEX:CANF	Can Fite BioPharma Ltd
11/07/2024	08:00	GlobeNewswire Inc.	Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer	AMEX:CANF	Can Fite BioPharma Ltd
01/07/2024	08:00	GlobeNewswire Inc.	Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson	AMEX:CANF	Can Fite BioPharma Ltd
28/06/2024	08:00	Business Wire	Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix	AMEX:CANF	Can Fite BioPharma Ltd
24/06/2024	08:00	Business Wire	Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	AMEX:CANF	Can Fite BioPharma Ltd
10/06/2024	08:00	Business Wire	Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	AMEX:CANF	Can Fite BioPharma Ltd
07/06/2024	17:15	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	AMEX:CANF	Can Fite BioPharma Ltd
05/06/2024	08:00	Business Wire	Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study	AMEX:CANF	Can Fite BioPharma Ltd
29/05/2024	08:00	Business Wire	Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases	AMEX:CANF	Can Fite BioPharma Ltd
27/05/2024	08:00	Business Wire	Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024	AMEX:CANF	Can Fite BioPharma Ltd
23/05/2024	08:00	Business Wire	Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6	AMEX:CANF	Can Fite BioPharma Ltd
13/05/2024	08:00	Business Wire	Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	AMEX:CANF	Can Fite BioPharma Ltd
09/05/2024	08:00	Business Wire	Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	AMEX:CANF	Can Fite BioPharma Ltd